Please assess the completion status of the following clinical trial:

Trial Title: Intracavernosal Injection of Botulinum Toxin Type A in the Treatment of Vascular Erectile Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 24 males will be included in the study recruited from Andrology, Sexology \& STD's outpatient clinic, Kasr El Aini Hospitals, Cairo University, complaining of Vascular ED proved by penile duplex.~* Unable to develop erections sufficient for intercourse.~* Failing to respond to first line and second line treatments for Erectile Dysfunction with surgery as the only remaining treatment option.~* Age between 40 to 70 years.~Exclusion Criteria:~* Significant cardiovascular disease interfering with sexual activity

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- (BTX) A Group (Type: EXPERIMENTAL): The treatment group will be injected intracavernously with a trimix solution for colour Doppler assessment, followed, on a separate day by 50 units of Botulinum toxin (BTX) A.
- Saline Group (Type: PLACEBO_COMPARATOR): The control group, 12 patients, will be injected with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) during penile colour Doppler assessment followed on a separate day with a normal saline injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).